secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K/A
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-019977
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1 2023 revenues jump 239% to $41M; loss from ops down 72%
-------------------------------------------------------------------

- Total revenues $40.6M, +239% vs Q1 2022; Tyvaso DPI contributed $23M (services + royalties).
- Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M after Q2 2022 acquisition.
- Loss from operations narrowed 72% to $6M; commercial product gross margin 69%.
- Cash and investments $166.6M at March 31, 2023; R&D spend up to $5.6M for pipeline.
- CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial planned H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017023019977/0000950170-23-019977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017023019977/mnkd-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer